Literature DB >> 3752968

Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.

R Kurlan, A J Rubin, C Miller, L Rivera-Calimlim, A Clarke, I Shoulson.   

Abstract

The pathogenesis of on-off motor fluctuations in parkinsonism remains incompletely understood, but slowed or erratic gastric emptying of orally administered levodopa may be involved. In 3 patients with resistant on-off fluctuations, direct duodenal continuous infusion of levodopa via a nasoduodenal tube resulted in a heightened therapeutic effect, including a reduction in motor fluctuations. In 1 of these patients, continuous duodenal levodopa infusion produced greater benefit than did intermittent duodenal levodopa administration. Direct duodenal delivery of levodopa lessens the problems with gastric emptying and may be suitable for long-term therapy in selected patients with resistant on-off motor fluctuations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3752968     DOI: 10.1002/ana.410200213

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  28 in total

Review 1.  The on-off phenomenon.

Authors:  A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 2.  What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Authors:  Rüdiger Hilker; Angelo Antonini; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

3.  Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.

Authors:  D Deleu; G Ebinger; Y Michotte
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  The influence of levodopa on gastric emptying in man.

Authors:  D R Robertson; A G Renwick; N D Wood; N Cross; B S Macklin; J S Fleming; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

5.  Levodopa availability improves with progression of Parkinson's disease.

Authors:  Dirk Woitalla; Oliver Goetze; Jeong I Kim; Alice B Nikodem; Wolfgang E Schmidt; Horst Przuntek; Thomas Müller
Journal:  J Neurol       Date:  2006-04-28       Impact factor: 4.849

Review 6.  The use of thalamotomy in the treatment of levodopa-induced dyskinesia.

Authors:  R D Page
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

7.  Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease.

Authors:  S A Factor; J R Sanchez-Ramos; W J Weiner; A M Ingenito
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

Review 8.  Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.

Authors:  Karin Wirdefeldt; Per Odin; Dag Nyholm
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

9.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

Authors:  C Warren Olanow; Karl Kieburtz; Per Odin; Alberto J Espay; David G Standaert; Hubert H Fernandez; Arvydas Vanagunas; Ahmed A Othman; Katherine L Widnell; Weining Z Robieson; Yili Pritchett; Krai Chatamra; Janet Benesh; Robert A Lenz; Angelo Antonini
Journal:  Lancet Neurol       Date:  2013-12-20       Impact factor: 44.182

10.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.